VKTX
Viking Therapeutics, Inc.35.72
-0.43-1.19%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
4.04BP/E (TTM)
-Basic EPS (TTM)
-2.12Dividend Yield
0%Recent Filings
8-K
Viking's obesity trials progress
Viking Therapeutics reported Q3 2025 net loss of $90.8 million, up from $24.9 million last year, driven by $90.0 million in R&D expenses for obesity drug VK2735's Phase 3 VANQUISH trials, on track with enrollment completion in VANQUISH-1 by year-end. The oral VK2735 Phase 2 trial hit endpoints with up to 12.2% mean weight loss over 13 weeks, showing strong tolerability. Cash stands at $715 million. Phase 3 advances solidify pipeline momentum.
8-K
VK2735 oral hits 12.2% weight loss
Viking Therapeutics unveiled positive Phase 2 results for its oral VK2735 tablet on August 19, 2025, showing up to 12.2% mean weight loss after 13 weeks versus 1.3% for placebo in obese patients. The dual GLP-1/GIP agonist proved safe, with 99% of GI side effects mild or moderate, and discontinuation rates comparable to placebo. Weight maintenance held steady after down-titrating from 90 mg to 30 mg. This bolsters Viking's obesity pipeline, yet clinical risks persist.
10-Q
Q2 FY2025 results
Viking Therapeutics posted no revenue in Q2 FY2025 ended June 30, 2025, with operating expenses climbing to $74.6M from $34.1M y/y, driven by R&D ramp-up to $60.2M from $23.8M as clinical programs advance. This yielded an operating loss of $74.6M, up from $34.1M y/y, while net loss widened to $65.6M or $(0.58) per diluted share from $22.3M or $(0.20), reconciled against 112.1M weighted shares with no anti-dilution effects. Cash burn hit $99.4M in operating activities for the half-year, yet liquidity stays robust at $807.7M in cash equivalents and short-term investments, debt-free. Free cash flow not disclosed in the 10-Q. Signed multi-year manufacturing pacts in March 2025 for VK2735 API and fill/finish, with prepayments through 2028 credited to future orders. Clinical momentum builds. Pipeline delays pose risks.
8-K
Viking advances obesity trials
Viking Therapeutics reported a Q2 2025 net loss of $65.6 million, up from $22.3 million last year, driven by ramped-up R&D spending on obesity drug VK2735. The company kicked off Phase 3 VANQUISH trials for subcutaneous VK2735 in obesity patients, targeting 4,500 and 1,100 enrollees respectively, while wrapping enrollment in the Phase 2 oral VK2735 study with data due 2H25. Cash reserves stand at $808 million, fueling pipeline advances. Yet risks loom in trial outcomes.
8-K
Annual meeting results disclosed
Viking Therapeutics held its 2025 Annual Meeting on May 20, with 68.3% of shares represented. Stockholders elected Matthew W. Foehr and Charles A. Rowland, Jr. as Class I directors until 2028, despite significant withheld votes. They ratified CBIZ CPAs P.C. as auditors for the fiscal year ending December 31, 2025. Advisory approval passed for executive compensation, but with notable opposition. Governance continuity holds firm.
IPO
Employees
Sector
Industry
ATOS
Atossa Therapeutics, Inc.
0.72+0.01
CRNX
Crinetics Pharmaceuticals, Inc.
48.61-0.71
IKT
Inhibikase Therapeutics, Inc.
1.60-0.02
MBX
MBX Biosciences, Inc.
27.75-0.63
OSRH
OSR Holdings, Inc.
0.55-0.02
SGMT
Sagimet Biosciences Inc. - Seri
6.05+0.02
VRTX
Vertex Pharmaceuticals Incorpor
454.96-0.75
VTVT
vTv Therapeutics Inc.
35.14+1.38
VTYX
Ventyx Biosciences, Inc.
8.21-0.13
VYGR
Voyager Therapeutics, Inc.
4.42+0.06